$GH
Guardant Health, Inc.

2022 Q1 Form 10-Q Financial Statement

#000157628022000026 Filed on May 05, 2022

View on sec.gov

Income Statement

Concept 2022 Q1 2021 Q1
Revenue $96.10M $78.67M
YoY Change 22.16% 16.52%
Cost Of Revenue $31.98M $28.75M
YoY Change 11.24% 40.18%
Gross Profit $64.12M $49.92M
YoY Change 28.44% 6.21%
Gross Profit Margin 66.72% 63.46%
Selling, General & Admin $105.7M $102.3M
YoY Change 3.35% 127.78%
% of Gross Profit 164.85% 204.87%
Research & Development $81.76M $55.51M
YoY Change 47.29% 49.96%
% of Gross Profit 127.51% 111.19%
Depreciation & Amortization $7.201M $5.010M
YoY Change 43.73% 51.63%
% of Gross Profit 11.23% 10.04%
Operating Expenses $187.5M $157.8M
YoY Change 18.81% 92.61%
Operating Profit -$123.3M -$107.9M
YoY Change 14.35% 208.96%
Interest Expense $644.0K $646.0K
YoY Change -0.31% 5283.33%
% of Operating Profit
Other Income/Expense, Net -$48.00K -$290.0K
YoY Change -83.45% 38.76%
Pretax Income -$123.3M -$107.2M
YoY Change 14.92% 237.1%
Income Tax -$24.00K $110.0K
% Of Pretax Income
Net Earnings -$123.2M -$107.4M
YoY Change 14.78% 237.3%
Net Earnings / Revenue -128.23% -136.47%
Basic Earnings Per Share -$1.21 -$1.09
Diluted Earnings Per Share -$1.21 -$1.09
COMMON SHARES
Basic Shares Outstanding 101.9M shares 101.0M shares
Diluted Shares Outstanding 101.9M shares 101.0M shares

Balance Sheet

Concept 2022 Q1 2021 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $962.3M $1.941B
YoY Change -50.41% 273.1%
Cash & Equivalents $573.6M $869.4M
Short-Term Investments $388.7M $1.071B
Other Short-Term Assets $30.07M $15.70M
YoY Change 91.53% 11.35%
Inventory $36.61M $28.88M
Prepaid Expenses
Receivables $84.33M $48.04M
Other Receivables $0.00 $0.00
Total Short-Term Assets $1.113B $2.033B
YoY Change -45.24% 234.72%
LONG-TERM ASSETS
Property, Plant & Equipment $151.3M $71.77M
YoY Change 110.86% 53.72%
Goodwill $3.290M $3.290M
YoY Change 0.0% 0.0%
Intangibles $13.73M $15.67M
YoY Change -12.42% -11.35%
Long-Term Investments $588.5M $0.00
YoY Change -100.0%
Other Assets $70.92M $17.30M
YoY Change 310.01% 266.38%
Total Long-Term Assets $1.016B $313.7M
YoY Change 223.98% -7.95%
TOTAL ASSETS
Total Short-Term Assets $1.113B $2.033B
Total Long-Term Assets $1.016B $313.7M
Total Assets $2.130B $2.347B
YoY Change -9.25% 147.5%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $32.23M $22.32M
YoY Change 44.41% -8.45%
Accrued Expenses $51.85M $27.64M
YoY Change 87.57% 19.81%
Deferred Revenue $10.57M $8.360M
YoY Change 26.44%
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $228.8M $95.50M
YoY Change 139.59% 16.01%
LONG-TERM LIABILITIES
Long-Term Debt $1.135B $1.133B
YoY Change 0.23%
Other Long-Term Liabilities $6.909M $1.651M
YoY Change 318.47% 13.16%
Total Long-Term Liabilities $6.909M $1.651M
YoY Change 318.47% 13.16%
TOTAL LIABILITIES
Total Short-Term Liabilities $228.8M $95.50M
Total Long-Term Liabilities $6.909M $1.651M
Total Liabilities $1.597B $1.440B
YoY Change 10.85% 1125.22%
SHAREHOLDERS EQUITY
Retained Earnings -$1.131B -$711.8M
YoY Change 58.9% 87.05%
Common Stock
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $533.0M $847.0M
YoY Change
Total Liabilities & Shareholders Equity $2.130B $2.347B
YoY Change -9.25% 147.5%

Cashflow Statement

Concept 2022 Q1 2021 Q1
OPERATING ACTIVITIES
Net Income -$123.2M -$107.4M
YoY Change 14.78% 237.3%
Depreciation, Depletion And Amortization $7.201M $5.010M
YoY Change 43.73% 51.63%
Cash From Operating Activities -$28.62M -$16.29M
YoY Change 75.67% 22.65%
INVESTING ACTIVITIES
Capital Expenditures $22.70M $9.586M
YoY Change 136.8% -0.13%
Acquisitions
YoY Change
Other Investing Activities $133.5M $133.5M
YoY Change 0.04% 176.37%
Cash From Investing Activities $110.8M $123.9M
YoY Change -10.54% 495.41%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities -$12.00K -$69.95M
YoY Change -99.98% -4871.69%
NET CHANGE
Cash From Operating Activities -$28.62M -$16.29M
Cash From Investing Activities $110.8M $123.9M
Cash From Financing Activities -$12.00K -$69.95M
Net Change In Cash $81.39M $36.54M
YoY Change 122.73% 305.49%
FREE CASH FLOW
Cash From Operating Activities -$28.62M -$16.29M
Capital Expenditures $22.70M $9.586M
Free Cash Flow -$51.32M -$25.88M
YoY Change 98.32% 13.1%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2022Q1 dei Amendment Flag
AmendmentFlag
false
CY2022Q1 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2022
CY2022Q1 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q1
CY2022Q1 dei Entity Central Index Key
EntityCentralIndexKey
0001576280
CY2022Q1 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2020 us-gaap Accounting Standards Update Extensible List
AccountingStandardsUpdateExtensibleList
http://fasb.org/us-gaap/2021-01-31#AccountingStandardsUpdate202006Member
CY2022Q1 dei Document Type
DocumentType
10-Q
CY2022Q1 dei Document Quarterly Report
DocumentQuarterlyReport
true
CY2022Q1 dei Document Period End Date
DocumentPeriodEndDate
2022-03-31
CY2022Q1 dei Document Transition Report
DocumentTransitionReport
false
CY2022Q1 dei Entity File Number
EntityFileNumber
001-38683
CY2022Q1 dei Entity Tax Identification Number
EntityTaxIdentificationNumber
45-4139254
CY2022Q1 dei Entity Registrant Name
EntityRegistrantName
GUARDANT HEALTH, INC.
CY2022Q1 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
CY2022Q1 dei Entity Address Address Line1
EntityAddressAddressLine1
3000 Hanover Street
CY2022Q1 dei Entity Address City Or Town
EntityAddressCityOrTown
Palo Alto
CY2022Q1 dei Entity Address State Or Province
EntityAddressStateOrProvince
CA
CY2022Q1 dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
94304
CY2022Q1 dei City Area Code
CityAreaCode
855
CY2022Q1 dei Local Phone Number
LocalPhoneNumber
698-8887
CY2022Q1 dei Security12b Title
Security12bTitle
Common Stock, $0.00001 par value per share
CY2022Q1 dei Trading Symbol
TradingSymbol
GH
CY2022Q1 dei Security Exchange Name
SecurityExchangeName
NASDAQ
CY2022Q1 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2022Q1 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2022Q1 dei Entity Filer Category
EntityFilerCategory
Large Accelerated Filer
CY2022Q1 dei Entity Small Business
EntitySmallBusiness
false
CY2022Q1 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
CY2022Q1 dei Entity Shell Company
EntityShellCompany
false
CY2022Q2 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
101923322 shares
CY2022Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
573604000 USD
CY2021Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
492202000 USD
CY2022Q1 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
388662000 USD
CY2021Q4 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
440546000 USD
CY2022Q1 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
84331000 USD
CY2021Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
97652000 USD
CY2022Q1 us-gaap Inventory Net
InventoryNet
36613000 USD
CY2021Q4 us-gaap Inventory Net
InventoryNet
30674000 USD
CY2022Q1 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
30070000 USD
CY2021Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
53052000 USD
CY2022Q1 us-gaap Assets Current
AssetsCurrent
1113280000 USD
CY2021Q4 us-gaap Assets Current
AssetsCurrent
1114126000 USD
CY2022Q1 us-gaap Marketable Securities Noncurrent
MarketableSecuritiesNoncurrent
588453000 USD
CY2021Q4 us-gaap Marketable Securities Noncurrent
MarketableSecuritiesNoncurrent
698034000 USD
CY2022Q1 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
151322000 USD
CY2021Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
124461000 USD
CY2022Q1 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
188607000 USD
CY2021Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
189443000 USD
CY2022Q1 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
13727000 USD
CY2021Q4 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
14207000 USD
CY2022Q1 us-gaap Goodwill
Goodwill
3290000 USD
CY2021Q4 us-gaap Goodwill
Goodwill
3290000 USD
CY2022Q1 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
70919000 USD
CY2021Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
60938000 USD
CY2022Q1 us-gaap Assets
Assets
2129598000 USD
CY2021Q4 us-gaap Assets
Assets
2204499000 USD
CY2022Q1 us-gaap Accounts Payable Current
AccountsPayableCurrent
32230000 USD
CY2021Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
17580000 USD
CY2022Q1 us-gaap Deferred Compensation Liability Current
DeferredCompensationLiabilityCurrent
56158000 USD
CY2021Q4 us-gaap Deferred Compensation Liability Current
DeferredCompensationLiabilityCurrent
42496000 USD
CY2022Q1 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
51851000 USD
CY2021Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
45285000 USD
CY2022Q1 gh Investments Payable
InvestmentsPayable
78000000 USD
CY2021Q4 gh Investments Payable
InvestmentsPayable
78000000 USD
CY2022Q1 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
10570000 USD
CY2021Q4 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
11326000 USD
CY2022Q1 us-gaap Liabilities Current
LiabilitiesCurrent
228809000 USD
CY2021Q4 us-gaap Liabilities Current
LiabilitiesCurrent
194687000 USD
CY2022Q1 us-gaap Convertible Debt Noncurrent
ConvertibleDebtNoncurrent
1135463000 USD
CY2021Q4 us-gaap Convertible Debt Noncurrent
ConvertibleDebtNoncurrent
1134821000 USD
CY2022Q1 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
225377000 USD
CY2021Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
226053000 USD
CY2022Q1 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
6909000 USD
CY2021Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
3933000 USD
CY2022Q1 us-gaap Liabilities
Liabilities
1596558000 USD
CY2021Q4 us-gaap Liabilities
Liabilities
1559494000 USD
CY2022Q1 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.00001
CY2021Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.00001
CY2021Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000 shares
CY2022Q1 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000 shares
CY2022Q1 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2021Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2022Q1 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2021Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2022Q1 us-gaap Preferred Stock Value Outstanding
PreferredStockValueOutstanding
0 USD
CY2021Q4 us-gaap Preferred Stock Value Outstanding
PreferredStockValueOutstanding
0 USD
CY2022Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.00001
CY2021Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.00001
CY2021Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
350000000 shares
CY2022Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
350000000 shares
CY2022Q1 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
101895835 shares
CY2022Q1 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
101895835 shares
CY2021Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
101767446 shares
CY2021Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
101767446 shares
CY2022Q1 us-gaap Common Stock Value Outstanding
CommonStockValueOutstanding
1000 USD
CY2021Q4 us-gaap Common Stock Value Outstanding
CommonStockValueOutstanding
1000 USD
CY2022Q1 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
1682406000 USD
CY2021Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
1657593000 USD
CY2022Q1 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-18314000 USD
CY2021Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-4764000 USD
CY2022Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-1131053000 USD
CY2021Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-1007825000 USD
CY2022Q1 us-gaap Stockholders Equity
StockholdersEquity
533040000 USD
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
645005000 USD
CY2022Q1 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
2129598000 USD
CY2021Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
2204499000 USD
CY2022Q1 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-12758000 USD
CY2022Q1 gh Revenue From Precision Oncology Testing
RevenueFromPrecisionOncologyTesting
84136000 USD
CY2021Q1 gh Revenue From Precision Oncology Testing
RevenueFromPrecisionOncologyTesting
63729000 USD
CY2022Q1 gh Revenue From Development Services
RevenueFromDevelopmentServices
11963000 USD
CY2021Q1 gh Revenue From Development Services
RevenueFromDevelopmentServices
14936000 USD
CY2022Q1 us-gaap Revenues
Revenues
96099000 USD
CY2021Q1 us-gaap Revenues
Revenues
78665000 USD
CY2022Q1 gh Costs Of Precision Oncology Testing
CostsOfPrecisionOncologyTesting
30684000 USD
CY2021Q1 gh Costs Of Precision Oncology Testing
CostsOfPrecisionOncologyTesting
23590000 USD
CY2022Q1 gh Cost Of Development Services
CostOfDevelopmentServices
1297000 USD
CY2021Q1 gh Cost Of Development Services
CostOfDevelopmentServices
5157000 USD
CY2022Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
81757000 USD
CY2021Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
55508000 USD
CY2022Q1 us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
64432000 USD
CY2021Q1 us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
34338000 USD
CY2022Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
41267000 USD
CY2021Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
67935000 USD
CY2022Q1 us-gaap Costs And Expenses
CostsAndExpenses
219437000 USD
CY2021Q1 us-gaap Costs And Expenses
CostsAndExpenses
186528000 USD
CY2022Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-123338000 USD
CY2021Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-107863000 USD
CY2022Q1 us-gaap Investment Income Interest
InvestmentIncomeInterest
778000 USD
CY2021Q1 us-gaap Investment Income Interest
InvestmentIncomeInterest
1551000 USD
CY2022Q1 us-gaap Interest Expense
InterestExpense
644000 USD
CY2021Q1 us-gaap Interest Expense
InterestExpense
646000 USD
CY2022Q1 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-48000 USD
CY2021Q1 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-290000 USD
CY2022Q1 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-123252000 USD
CY2021Q1 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-107248000 USD
CY2022Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-24000 USD
CY2021Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
110000 USD
CY2022Q1 us-gaap Profit Loss
ProfitLoss
-123228000 USD
CY2021Q1 us-gaap Profit Loss
ProfitLoss
-107358000 USD
CY2022Q1 us-gaap Net Income Loss Attributable To Redeemable Noncontrolling Interest
NetIncomeLossAttributableToRedeemableNoncontrollingInterest
0 USD
CY2021Q1 us-gaap Net Income Loss Attributable To Redeemable Noncontrolling Interest
NetIncomeLossAttributableToRedeemableNoncontrollingInterest
2300000 USD
CY2022Q1 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-123228000 USD
CY2022Q1 us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-123228000 USD
CY2021Q1 us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-109658000 USD
CY2021Q1 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-109658000 USD
CY2022Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.21
CY2022Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.21
CY2021Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.09
CY2021Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.09
CY2022Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
101853000 shares
CY2022Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
101853000 shares
CY2021Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
100955000 shares
CY2021Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
100955000 shares
CY2022Q1 us-gaap Profit Loss
ProfitLoss
-123228000 USD
CY2021Q1 us-gaap Profit Loss
ProfitLoss
-107358000 USD
CY2021Q1 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-706000 USD
CY2022Q1 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax
-792000 USD
CY2021Q1 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax
-1087000 USD
CY2022Q1 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-13550000 USD
CY2021Q1 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-1793000 USD
CY2022Q1 us-gaap Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
-136778000 USD
CY2021Q1 us-gaap Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
-109151000 USD
CY2022Q1 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Noncontrolling Interest
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToNoncontrollingInterest
0 USD
CY2021Q1 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Noncontrolling Interest
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToNoncontrollingInterest
2300000 USD
CY2022Q1 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-136778000 USD
CY2021Q1 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-111451000 USD
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
645005000 USD
CY2022Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
963000 USD
CY2022Q1 gh Stock Issued During Period Value Exercise Of Warrants
StockIssuedDuringPeriodValueExerciseOfWarrants
8000 USD
CY2022Q1 us-gaap Adjustments Related To Tax Withholding For Share Based Compensation
AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation
957000 USD
CY2022Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
24799000 USD
CY2022Q1 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-13550000 USD
CY2022Q1 us-gaap Profit Loss
ProfitLoss
-123228000 USD
CY2022Q1 us-gaap Stockholders Equity
StockholdersEquity
533040000 USD
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
1298495000 USD
CY2021Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
4462000 USD
CY2021Q1 gh Stock Issued During Period Value Exercise Of Warrants
StockIssuedDuringPeriodValueExerciseOfWarrants
13000 USD
CY2021Q1 us-gaap Adjustments Related To Tax Withholding For Share Based Compensation
AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation
73576000 USD
CY2021Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
55069000 USD
CY2021Q1 us-gaap Reclassifications Of Temporary To Permanent Equity
ReclassificationsOfTemporaryToPermanentEquity
-2300000 USD
CY2021Q1 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-1793000 USD
CY2021Q1 us-gaap Profit Loss
ProfitLoss
-107358000 USD
CY2021Q1 us-gaap Stockholders Equity
StockholdersEquity
847046000 USD
CY2022Q1 us-gaap Profit Loss
ProfitLoss
-123228000 USD
CY2021Q1 us-gaap Profit Loss
ProfitLoss
-107358000 USD
CY2022Q1 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
7201000 USD
CY2021Q1 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
5010000 USD
CY2022Q1 gh Non Cash Operating Lease Costs
NonCashOperatingLeaseCosts
6949000 USD
CY2021Q1 gh Non Cash Operating Lease Costs
NonCashOperatingLeaseCosts
3932000 USD
CY2022Q1 us-gaap Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1
BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
2390000 USD
CY2021Q1 us-gaap Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1
BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
0 USD
CY2022Q1 us-gaap Share Based Compensation
ShareBasedCompensation
24799000 USD
CY2021Q1 us-gaap Share Based Compensation
ShareBasedCompensation
55069000 USD
CY2022Q1 us-gaap Amortization Of Financing Costs
AmortizationOfFinancingCosts
642000 USD
CY2021Q1 us-gaap Amortization Of Financing Costs
AmortizationOfFinancingCosts
641000 USD
CY2022Q1 us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
-2449000 USD
CY2021Q1 us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
-3259000 USD
CY2022Q1 us-gaap Other Noncash Income Expense
OtherNoncashIncomeExpense
-21000 USD
CY2021Q1 us-gaap Other Noncash Income Expense
OtherNoncashIncomeExpense
0 USD
CY2022Q1 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-13299000 USD
CY2021Q1 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-5260000 USD
CY2022Q1 us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
5937000 USD
CY2021Q1 us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
6160000 USD
CY2022Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-21882000 USD
CY2021Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-521000 USD
CY2022Q1 us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
-3846000 USD
CY2021Q1 us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
-1202000 USD
CY2022Q1 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-753000 USD
CY2021Q1 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
11986000 USD
CY2022Q1 us-gaap Increase Decrease In Employee Related Liabilities
IncreaseDecreaseInEmployeeRelatedLiabilities
13662000 USD
CY2021Q1 us-gaap Increase Decrease In Employee Related Liabilities
IncreaseDecreaseInEmployeeRelatedLiabilities
8900000 USD
CY2022Q1 us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
8022000 USD
CY2021Q1 us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
4399000 USD
CY2022Q1 gh Increase Decrease In Operating Lease Liabilities
IncreaseDecreaseInOperatingLeaseLiabilities
-3106000 USD
CY2021Q1 gh Increase Decrease In Operating Lease Liabilities
IncreaseDecreaseInOperatingLeaseLiabilities
-2762000 USD
CY2022Q1 us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
-757000 USD
CY2021Q1 us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
-190000 USD
CY2022Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-28619000 USD
CY2021Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-16291000 USD
CY2022Q1 us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
163742000 USD
CY2021Q1 us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
70654000 USD
CY2022Q1 us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
310000000 USD
CY2021Q1 us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
204110000 USD
CY2022Q1 us-gaap Payments To Acquire Equity Securities Fv Ni
PaymentsToAcquireEquitySecuritiesFvNi
12750000 USD
CY2021Q1 us-gaap Payments To Acquire Equity Securities Fv Ni
PaymentsToAcquireEquitySecuritiesFvNi
0 USD
CY2022Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
22700000 USD
CY2021Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
9586000 USD
CY2022Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
110808000 USD
CY2021Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
123870000 USD
CY2022Q1 us-gaap Finance Lease Principal Payments
FinanceLeasePrincipalPayments
18000 USD
CY2021Q1 us-gaap Finance Lease Principal Payments
FinanceLeasePrincipalPayments
55000 USD
CY2022Q1 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
963000 USD
CY2021Q1 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
4462000 USD
CY2022Q1 us-gaap Payments Related To Tax Withholding For Share Based Compensation
PaymentsRelatedToTaxWithholdingForShareBasedCompensation
957000 USD
CY2021Q1 us-gaap Payments Related To Tax Withholding For Share Based Compensation
PaymentsRelatedToTaxWithholdingForShareBasedCompensation
73576000 USD
CY2022Q1 us-gaap Payments Of Debt Issuance Costs
PaymentsOfDebtIssuanceCosts
0 USD
CY2021Q1 us-gaap Payments Of Debt Issuance Costs
PaymentsOfDebtIssuanceCosts
784000 USD
CY2022Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-12000 USD
CY2021Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-69953000 USD
CY2022Q1 us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
-792000 USD
CY2021Q1 us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
-1087000 USD
CY2022Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
81385000 USD
CY2021Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
36539000 USD
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
492288000 USD
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
832977000 USD
CY2022Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
573673000 USD
CY2021Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
869516000 USD
CY2022Q1 us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
3940000 USD
CY2021Q1 us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
170847000 USD
CY2022Q1 us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
19751000 USD
CY2021Q1 us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
5881000 USD
CY2022Q1 gh Equity Security Fvni Impairment Or Adjustments To Carrying Value
EquitySecurityFVNIImpairmentOrAdjustmentsToCarryingValue
0 USD
CY2022Q1 us-gaap Contract With Customer Asset Net
ContractWithCustomerAssetNet
3100000 USD
CY2022Q1 gh Property Plant And Equipment Acquired Under Finance Leases
PropertyPlantAndEquipmentAcquiredUnderFinanceLeases
0 USD
CY2021Q1 gh Property Plant And Equipment Acquired Under Finance Leases
PropertyPlantAndEquipmentAcquiredUnderFinanceLeases
238000 USD
CY2022Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
573604000 USD
CY2021Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
869372000 USD
CY2022Q1 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
69000 USD
CY2021Q1 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
144000 USD
CY2022Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
573673000 USD
CY2021Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
869516000 USD
CY2021Q4 us-gaap Equity Securities Fv Ni
EquitySecuritiesFvNi
39400000 USD
CY2022Q1 us-gaap Use Of Estimates
UseOfEstimates
<div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of condensed consolidated financial statements in conformity with GAAP requires management to make certain estimates, judgments and assumptions that affect the reported amounts of assets and liabilities and the related disclosures at the date of the condensed consolidated financial statements, as well as the reported amounts of revenues and expenses during the periods presented. The Company bases its estimates on historical experience and other market-specific or other relevant assumptions that it believes to be reasonable under the circumstances. Estimates are used in several areas including, but not limited to, estimation of variable consideration, estimation of credit losses, standalone selling price allocation included in contracts with multiple performance obligations, </span></div>goodwill and identifiable intangible assets, stock-based compensation, incremental borrowing rate for operating leases, contingencies, certain inputs into the provision for (benefit from) income taxes, including related reserves, valuation of non-marketable securities, valuation of redeemable noncontrolling interest and noncontrolling interest liability, among others. These estimates generally involve complex issues and require judgments, involve the analysis of historical results and prediction of future trends, can require extended periods of time to resolve and are subject to change from period to period. Actual results may differ materially from management’s estimates. The severity of the impact on the Company's business for the remainder of calendar year 2022 and beyond will depend on a number of factors, including, but not limited to, the duration and severity of the pandemic, and the impact of any variants of the virus, the extent and severity of the impact on the Company's customers and suppliers, the continued disruption to demand for the Company's products and services, and the impact of the global business and economic environment on liquidity and the availability of capital, all of which are uncertain and cannot be predicted.
CY2022Q1 us-gaap Restricted Cash
RestrictedCash
100000 USD
CY2021Q4 us-gaap Restricted Cash
RestrictedCash
100000 USD
CY2022Q1 us-gaap Equity Securities Fv Ni
EquitySecuritiesFvNi
52200000 USD
CY2020Q3 gh Contractual Receivables Term
ContractualReceivablesTerm
P6Y
CY2020Q4 gh Proceeds From Contractual Receivable
ProceedsFromContractualReceivable
1000000 USD
CY2022Q1 us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">Concentration of Risk</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is subject to credit risk from its portfolio of cash equivalents held at one commercial bank and investments in marketable securities. The Company limits its exposure to credit losses by investing in money market funds through a U.S. bank with high credit ratings. The Company’s cash may consist of deposits held with banks that may at times exceed federally insured limits, however, its exposure to credit risk in the event of default by the financial institution is limited to the extent of amounts recorded on the condensed consolidated balance sheets. The Company performs evaluations of the relative credit standing of these financial institutions to limit the amount of credit exposure. </span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company also invests in investment-grade debt instruments and has policy limits for the amount it can invest in any one type of security, except for securities issued or guaranteed by the U.S. government. The goals of the Company’s investment policy, in order of priority, are as follows: safety and preservation of principal and diversification of risk; liquidity of investments sufficient to meet cash flow requirements; and a competitive after-tax rate of return. Under its investment policy, the Company limits amounts invested in such securities by credit rating, maturity, investment type and issuer, as a result, the Company is not exposed to any significant concentrations of credit risk from these financial instruments.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is subject to credit risk from its accounts receivable. The majority of the Company’s accounts receivable arises from the provision of precision oncology services and development services and other in the United States and are primarily with biopharmaceutical companies with high credit ratings. The Company has not experienced any material losses related to receivables from individual customers, or groups of customers. The Company does not require collateral. Accounts receivable are recorded at net amount.</span></div>The Company is also subject to credit risk from its other receivables and other assets.
CY2020Q3 gh Contractual Receivables Before Allowance For Credit Loss
ContractualReceivablesBeforeAllowanceForCreditLoss
8000000 USD
CY2021Q4 gh Proceeds From Contractual Receivable
ProceedsFromContractualReceivable
1100000 USD
CY2022Q1 gh Contractual Receivables Credit Loss Expense Reversal Noncurrent
ContractualReceivablesCreditLossExpenseReversalNoncurrent
5900000 USD
CY2022Q1 gh Contractual Receivables Before Allowance For Credit Loss Gross Current
ContractualReceivablesBeforeAllowanceForCreditLossGrossCurrent
1100000 USD
CY2021Q4 gh Contractual Receivables Before Allowance For Credit Loss Gross Current
ContractualReceivablesBeforeAllowanceForCreditLossGrossCurrent
0 USD
CY2022Q1 gh Contractual Receivables Allowance For Credit Loss Current
ContractualReceivablesAllowanceForCreditLossCurrent
1100000 USD
CY2021Q4 gh Contractual Receivables Allowance For Credit Loss Current
ContractualReceivablesAllowanceForCreditLossCurrent
0 USD
CY2022Q1 gh Contractual Receivables After Allowance For Credit Loss Net Current
ContractualReceivablesAfterAllowanceForCreditLossNetCurrent
0 USD
CY2021Q4 gh Contractual Receivables After Allowance For Credit Loss Net Current
ContractualReceivablesAfterAllowanceForCreditLossNetCurrent
0 USD
CY2022Q1 gh Contractual Receivables Before Allowance For Credit Loss Gross Noncurrent
ContractualReceivablesBeforeAllowanceForCreditLossGrossNoncurrent
4800000 USD
CY2021Q4 gh Contractual Receivables Before Allowance For Credit Loss Gross Noncurrent
ContractualReceivablesBeforeAllowanceForCreditLossGrossNoncurrent
5900000 USD
CY2022Q1 gh Contractual Receivables Allowance For Credit Loss Noncurrent
ContractualReceivablesAllowanceForCreditLossNoncurrent
4800000 USD
CY2021Q4 gh Contractual Receivables Allowance For Credit Loss Noncurrent
ContractualReceivablesAllowanceForCreditLossNoncurrent
5900000 USD
CY2022Q1 gh Contractual Receivables After Allowance For Credit Loss Net Noncurrent
ContractualReceivablesAfterAllowanceForCreditLossNetNoncurrent
0 USD
CY2021Q4 gh Contractual Receivables After Allowance For Credit Loss Net Noncurrent
ContractualReceivablesAfterAllowanceForCreditLossNetNoncurrent
0 USD
CY2021Q4 gh Contractual Receivables Allowance For Credit Loss Current
ContractualReceivablesAllowanceForCreditLossCurrent
0 USD
CY2020Q4 gh Contractual Receivables Allowance For Credit Loss Current
ContractualReceivablesAllowanceForCreditLossCurrent
0 USD
CY2022Q1 gh Contractual Receivables Credit Loss Reclassification Current
ContractualReceivablesCreditLossReclassificationCurrent
1100000 USD
CY2021Q1 gh Contractual Receivables Credit Loss Reclassification Current
ContractualReceivablesCreditLossReclassificationCurrent
1100000 USD
CY2022Q1 gh Contractual Receivables Allowance For Credit Loss Current
ContractualReceivablesAllowanceForCreditLossCurrent
1100000 USD
CY2021Q1 gh Contractual Receivables Allowance For Credit Loss Current
ContractualReceivablesAllowanceForCreditLossCurrent
1100000 USD
CY2021Q4 gh Contractual Receivables Allowance For Credit Loss Noncurrent
ContractualReceivablesAllowanceForCreditLossNoncurrent
5900000 USD
CY2020Q4 gh Contractual Receivables Allowance For Credit Loss Noncurrent
ContractualReceivablesAllowanceForCreditLossNoncurrent
7000000 USD
CY2022Q1 gh Contractual Receivables Credit Loss Reclassification Noncurrent
ContractualReceivablesCreditLossReclassificationNoncurrent
-1100000 USD
CY2021Q1 gh Contractual Receivables Credit Loss Reclassification Noncurrent
ContractualReceivablesCreditLossReclassificationNoncurrent
-1100000 USD
CY2022Q1 gh Contractual Receivables Allowance For Credit Loss Noncurrent
ContractualReceivablesAllowanceForCreditLossNoncurrent
4800000 USD
CY2021Q1 gh Contractual Receivables Allowance For Credit Loss Noncurrent
ContractualReceivablesAllowanceForCreditLossNoncurrent
5900000 USD
CY2021Q4 us-gaap Contract With Customer Asset Net
ContractWithCustomerAssetNet
5700000 USD
CY2022Q1 us-gaap Number Of Operating Segments
NumberOfOperatingSegments
1 segment
CY2022Q1 us-gaap Goodwill Impaired Accumulated Impairment Loss
GoodwillImpairedAccumulatedImpairmentLoss
0 USD
CY2022Q1 us-gaap Impairment Of Intangible Assets Excluding Goodwill
ImpairmentOfIntangibleAssetsExcludingGoodwill
0 USD
CY2022Q1 gh Post Acquisition Contingent Consideration Expense
PostAcquisitionContingentConsiderationExpense
2100000 USD
CY2021Q1 gh Post Acquisition Contingent Consideration Expense
PostAcquisitionContingentConsiderationExpense
0 USD
CY2022Q1 us-gaap Contract With Customer Liability Cumulative Catch Up Adjustment To Revenue Change In Estimate Of Transaction Price
ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice
2000000 USD
CY2021Q1 us-gaap Contract With Customer Liability Cumulative Catch Up Adjustment To Revenue Change In Estimate Of Transaction Price
ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice
5100000 USD
CY2022Q1 us-gaap Contract With Customer Liability
ContractWithCustomerLiability
10600000 USD
CY2021Q4 us-gaap Contract With Customer Liability
ContractWithCustomerLiability
11300000 USD
CY2022Q1 us-gaap Depreciation
Depreciation
6700000 USD
CY2021 us-gaap Contract With Customer Liability Revenue Recognized
ContractWithCustomerLiabilityRevenueRecognized
3500000 USD
CY2022Q1 us-gaap Contract With Customer Liability Revenue Recognized
ContractWithCustomerLiabilityRevenueRecognized
3500000 USD
CY2021Q1 us-gaap Contract With Customer Liability Revenue Recognized
ContractWithCustomerLiabilityRevenueRecognized
5000000 USD
CY2020 us-gaap Contract With Customer Liability Revenue Recognized
ContractWithCustomerLiabilityRevenueRecognized
5000000 USD
CY2022Q1 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
212804000 USD
CY2021Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
179285000 USD
CY2022Q1 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
61482000 USD
CY2021Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
54824000 USD
CY2022Q1 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
151322000 USD
CY2021Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
124461000 USD
CY2021Q1 us-gaap Depreciation
Depreciation
4500000 USD
CY2022Q1 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
16556000 USD
CY2021Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
12856000 USD
CY2022Q1 us-gaap Accrued Income Taxes Current
AccruedIncomeTaxesCurrent
4401000 USD
CY2021Q4 us-gaap Accrued Income Taxes Current
AccruedIncomeTaxesCurrent
4223000 USD
CY2022Q1 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
8410000 USD
CY2021Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
6994000 USD
CY2022Q1 gh Accrued Clinical Trials And Studies
AccruedClinicalTrialsAndStudies
5151000 USD
CY2021Q4 gh Accrued Clinical Trials And Studies
AccruedClinicalTrialsAndStudies
3332000 USD
CY2022Q1 gh Estimated Litigation Liability Legal Fees Current
EstimatedLitigationLiabilityLegalFeesCurrent
6429000 USD
CY2021Q4 gh Estimated Litigation Liability Legal Fees Current
EstimatedLitigationLiabilityLegalFeesCurrent
4166000 USD
CY2022Q1 gh Accrued Expenses Property And Equipment Current
AccruedExpensesPropertyAndEquipmentCurrent
1349000 USD
CY2021Q4 gh Accrued Expenses Property And Equipment Current
AccruedExpensesPropertyAndEquipmentCurrent
5893000 USD
CY2022Q1 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
9555000 USD
CY2021Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
7821000 USD
CY2022Q1 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
51851000 USD
CY2021Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
45285000 USD
CY2022Q1 gh Debt Securities Available For Sale And Cash And Cash Equivalents Amortized Cost
DebtSecuritiesAvailableForSaleAndCashAndCashEquivalentsAmortizedCost
1440497000 USD
CY2022Q1 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
0 USD
CY2022Q1 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
16350000 USD
CY2022Q1 us-gaap Goodwill
Goodwill
3290000 USD
CY2022Q1 gh Cash Cash Equivalents And Debt Securities Fair Value
CashCashEquivalentsAndDebtSecuritiesFairValue
1424147000 USD
CY2021Q4 gh Debt Securities Available For Sale And Cash And Cash Equivalents Amortized Cost
DebtSecuritiesAvailableForSaleAndCashAndCashEquivalentsAmortizedCost
1499957000 USD
CY2021Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
2000 USD
CY2021Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
3594000 USD
CY2021Q4 gh Cash Cash Equivalents And Debt Securities Fair Value
CashCashEquivalentsAndDebtSecuritiesFairValue
1496365000 USD
CY2022Q1 us-gaap Finite Lived Intangible Assets Gross
FiniteLivedIntangibleAssetsGross
16986000 USD
CY2022Q1 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
4859000 USD
CY2022Q1 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
12127000 USD
CY2022Q1 us-gaap Goodwill
Goodwill
3290000 USD
CY2022Q1 gh Intangible Assets Gross Including Goodwill
IntangibleAssetsGrossIncludingGoodwill
21876000 USD
CY2022Q1 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
4859000 USD
CY2022Q1 us-gaap Intangible Assets Net Including Goodwill
IntangibleAssetsNetIncludingGoodwill
17017000 USD
CY2021Q4 us-gaap Finite Lived Intangible Assets Gross
FiniteLivedIntangibleAssetsGross
16986000 USD
CY2021Q1 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
500000 USD
CY2021Q4 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
4379000 USD
CY2021Q4 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
12607000 USD
CY2021Q4 us-gaap Goodwill
Goodwill
3290000 USD
CY2021Q4 us-gaap Goodwill
Goodwill
3290000 USD
CY2021Q4 gh Intangible Assets Gross Including Goodwill
IntangibleAssetsGrossIncludingGoodwill
21876000 USD
CY2021Q4 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
4379000 USD
CY2021Q4 us-gaap Intangible Assets Net Including Goodwill
IntangibleAssetsNetIncludingGoodwill
17497000 USD
CY2022Q1 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
500000 USD
CY2022Q1 us-gaap Finite Lived Intangible Assets Amortization Expense Remainder Of Fiscal Year
FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear
1467000 USD
CY2022Q1 us-gaap Finite Lived Intangible Assets Amortization Expense Next Twelve Months
FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths
1947000 USD
CY2022Q1 us-gaap Finite Lived Intangible Assets Amortization Expense Year Two
FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo
1953000 USD
CY2022Q1 us-gaap Finite Lived Intangible Assets Amortization Expense Year Three
FiniteLivedIntangibleAssetsAmortizationExpenseYearThree
1670000 USD
CY2022Q1 us-gaap Finite Lived Intangible Assets Amortization Expense Year Four
FiniteLivedIntangibleAssetsAmortizationExpenseYearFour
1212000 USD
CY2022Q1 gh Finite Lived Intangible Assets Amortization Expense After Year Four
FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFour
3878000 USD
CY2022Q1 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
12127000 USD
CY2020Q4 gh Convertible Debt Hedge Strike Price
ConvertibleDebtHedgeStrikePrice
182.60
CY2020Q4 gh Convertible Debt Hedge Share Price Premium Percentage
ConvertibleDebtHedgeSharePricePremiumPercentage
0.75
CY2020Q4 us-gaap Share Price
SharePrice
104.34
CY2020Q4 gh Adjustments To Additional Paid In Capital Equity Component Of Convertible Debt Hedges
AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebtHedges
90000000 USD
CY2022Q1 us-gaap Operating Lease Expense
OperatingLeaseExpense
6900000 USD
CY2021Q1 us-gaap Operating Lease Expense
OperatingLeaseExpense
3900000 USD
CY2022Q1 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P9Y8M12D
CY2021Q4 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P10Y
CY2022Q1 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.0402
CY2021Q4 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.0401
CY2022Q1 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
17030000 USD
CY2022Q1 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
30363000 USD
CY2022Q1 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
32891000 USD
CY2022Q1 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
32238000 USD
CY2022Q1 us-gaap Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
27753000 USD
CY2022Q1 gh Lessee Operating Lease Liability Payments Due After Year Four
LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour
149637000 USD
CY2022Q1 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
289912000 USD
CY2022Q1 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
47979000 USD
CY2022Q1 us-gaap Operating Lease Liability
OperatingLeaseLiability
241933000 USD
CY2022Q1 us-gaap Dividends Common Stock
DividendsCommonStock
0 USD
CY2021 us-gaap Dividends Common Stock
DividendsCommonStock
0 USD
CY2022Q1 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
16973152 shares
CY2021Q4 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
13416775 shares
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
5231624 shares
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
2624974 shares
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
29.17
CY2021 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P6Y6M
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
193014000 USD
CY2022Q1 gh Share Based Compensation Arrangement By Share Based Payment Award Options Annual Increase In Shares Available
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAnnualIncreaseInSharesAvailable
3689000 shares
CY2022Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
7252 shares
CY2022Q1 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
62.10
CY2022Q1 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
105218 shares
CY2022Q1 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
5.94
CY2022Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
17502 shares
CY2022Q1 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
74.71
CY2022Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
8925158 shares
CY2022Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
2509506 shares
CY2022Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
29.92
CY2022Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P6Y3M18D
CY2022Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
115462000 USD
CY2022Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber
1957910 shares
CY2022Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
12.56
CY2022Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P5Y7M6D
CY2022Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
109604000 USD
CY2022Q1 gh Share Based Compensation Arrangement By Share Based Payment Award Options Annual Increase In Shares Available
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAnnualIncreaseInSharesAvailable
3689000 shares
CY2022Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
36.32
CY2021Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
101.21
CY2022Q1 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
27900000 USD
CY2022Q1 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P2Y10M24D
CY2022Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
24799000 USD
CY2021Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
55069000 USD
CY2022Q1 us-gaap Number Of Operating Segments
NumberOfOperatingSegments
1 segment
CY2022Q1 us-gaap Net Income Loss Attributable To Redeemable Noncontrolling Interest
NetIncomeLossAttributableToRedeemableNoncontrollingInterest
0 USD
CY2021Q1 us-gaap Net Income Loss Attributable To Redeemable Noncontrolling Interest
NetIncomeLossAttributableToRedeemableNoncontrollingInterest
2300000 USD
CY2022Q1 us-gaap Revenues
Revenues
96099000 USD
CY2022Q1 us-gaap Profit Loss
ProfitLoss
-123228000 USD
CY2021Q1 us-gaap Profit Loss
ProfitLoss
-107358000 USD
CY2022Q1 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-123228000 USD
CY2022Q1 us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-123228000 USD
CY2021Q1 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-109658000 USD
CY2021Q1 us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-109658000 USD
CY2022Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.21
CY2022Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.21
CY2021Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.09
CY2021Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.09
CY2022Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
101853000 shares
CY2022Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
101853000 shares
CY2021Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
100955000 shares
CY2021Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
100955000 shares
CY2022Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
14961000 shares
CY2021Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
15368000 shares
CY2021Q1 us-gaap Revenues
Revenues
78665000 USD

Files In Submission

Name View Source Status
0001576280-22-000026-index-headers.html Edgar Link pending
0001576280-22-000026-index.html Edgar Link pending
0001576280-22-000026.txt Edgar Link pending
0001576280-22-000026-xbrl.zip Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
gh-03312022x10qxex311.htm Edgar Link pending
gh-03312022x10qxex312.htm Edgar Link pending
gh-03312022x10qxex313.htm Edgar Link pending
gh-03312022x10qxex321.htm Edgar Link pending
gh-03312022x10qxex322.htm Edgar Link pending
gh-03312022x10qxex323.htm Edgar Link pending
gh-20220331.htm Edgar Link pending
gh-20220331.xsd Edgar Link pending
gh-20220331_cal.xml Edgar Link unprocessable
gh-20220331_def.xml Edgar Link unprocessable
gh-20220331_htm.xml Edgar Link completed
gh-20220331_lab.xml Edgar Link unprocessable
gh-20220331_pre.xml Edgar Link unprocessable
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R59.htm Edgar Link pending
R6.htm Edgar Link pending
R60.htm Edgar Link pending
R61.htm Edgar Link pending
R62.htm Edgar Link pending
R63.htm Edgar Link pending
R64.htm Edgar Link pending
R65.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
R9999.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending